{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-25-008512","form_type":"8-K/A","ticker":"PMCB","cik":"0001157075","company_name":"PharmaCyte Biotech, Inc.","filed_at":"2025-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.896716+00:00","generated_at":"2026-05-16T18:42:46.231694+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PharmaCyte acquires $3M convertible stake in Q/C Technologies; Q/C has going concern","bullets":["PharmaCyte bought Q/C Series H convertible preferred shares and warrants for $3M, convertible into 600,000 common shares each.","Q/C's auditors express substantial doubt about its ability to continue as a going concern due to net losses and negative cash flows.","Pro forma combined financials reflect the transaction; Q/C's financial statements show recurring operating losses.","Warrants expire five years after stockholder approval of issuance exceeding 19.99% of Q/C outstanding shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-25-008512","json":"https://secwatch.observer/filing/0001683168-25-008512.json","markdown":"https://secwatch.observer/filing/0001683168-25-008512.md","text":"https://secwatch.observer/filing/0001683168-25-008512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157075/000168316825008512/0001683168-25-008512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157075/000168316825008512/pharmacyte_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:42:46.231694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}